Search clinical trials for: BMS-986004 75 mg IV

Total 837 results

Bristol-Myers Squibb

Completed

Study to Evaluate Safety and Efficacy in Adult Subjects With ITP (ITP)

Immune Thrombocytopenic Purpura

United States, Australia, United Kingdom, Canada, Georgia, Moldova, Republic of, Poland, Russian Federation
Bristol-Myers Squibb

Completed

A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects

Rheumatoid Arthritis

United States
Hoffmann-La Roche

Completed

Placebo-Controlled, Single and Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986089 in Healthy Adult Subjects

Healthy Adults

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes

Diabetes Mellitus Type 2

United States, Canada
Bristol-Myers Squibb

Completed

Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States, Mexico, Australia, Colombia, Chile, Peru
Bristol-Myers Squibb

Completed

A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)

Healthy | Hepatitis C

United States, Puerto Rico
BioMarin Pharmaceutical

Terminated

Extension Study of BMN 044 in Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

Netherlands, Belgium, Italy, Sweden
Bristol-Myers Squibb

Completed

Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled Syringe

Healthy Participants

United States
Bristol-Myers Squibb

Completed

An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function

NAFLD | Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

Hungary, Czechia
Bristol-Myers Squibb

Completed

An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants

Cardiac Failure | Myocardial Failure

United States
Bristol-Myers Squibb

Completed

To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy Volunteers

Immunology

United States
Massachusetts General Hospital

Completed

A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults

Attention Deficit Hyperactivity Disorder

United States
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986036 Given to Healthy Participants

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis | Liver Fibrosis | Hepatic Cirrhosis

United States
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation

Non-Small Cell Lung Cancer、EGFR Sensitive Mutation

China
Bristol-Myers Squibb

Completed

Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors

Cancer

Australia, United States, Canada
Ayala Pharmaceuticals, Inc,

Completed

A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations (ACCURACY)

Adenoid Cystic Carcinoma

United States, Canada, France, United Kingdom, Israel, Netherlands
Bristol-Myers Squibb

Terminated

A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection Fraction

Heart Failure

Spain, United Kingdom, Netherlands, Czechia, Poland
Bristol-Myers Squibb

Withdrawn

A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Scleroderma

United Kingdom, United States, Poland, Canada
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986454 in Healthy Participants

Healthy Participants

United Kingdom
Bristol-Myers Squibb

Completed

A Study to Test the Effects of BMS-986036 on the Body in Healthy Japanese and Non-Japanese Subjects

Metabolics

United States
Bristol-Myers Squibb

Completed

A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

Non-Alcoholic Steatohepatitis

United States
Bristol-Myers Squibb

Completed

A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

Non-Alcoholic Steatohepatitis

United States
Bristol-Myers Squibb

Withdrawn

Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C

Hepatitis C Virus

United States
Bristol-Myers Squibb

Completed

A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (FRACTION-RCC)

Advanced Cancer

United States, Israel, Australia, Austria, Canada, Italy
Bristol-Myers Squibb

Withdrawn

A Study to Evaluate the Drug Levels and Safety of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean Participants

Healthy Participants

China, Korea, Republic of
Celgene

Recruiting

Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms

United States
Ruijin-Hainan Hospital Shanghai Jiao Tong University...

Recruiting

A Prospective Real World Study of Rimegepant in the Treatment of Migraine

Migraine

China
Edward Kim
Bristol-Myers Squibb; National Cancer Institute (NCI)

Terminated

BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditions

United States
Intergroupe Francophone de Cancerologie Thoracique

Recruiting

ENCOrafenib With Binimetinib in bRAF NSCLC (ENCO-BRAF)

Non Small Cell Lung Cancer | BRAF V600E

France
EMD Serono

Terminated

Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)

Lupus Erythematosus, Systemic

United States, Korea, Republic of, Bulgaria, Argentina, Mexico, Italy, Spain, Philippines, Germany, Czechia, Chile, Poland, Peru, United Kingdom, South Africa, Brazil, Russian Federation
Bristol-Myers Squibb

Completed

An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment (ADVISE)

Advanced Cancer

United States
Bristol-Myers Squibb

Active, not recruiting

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Advanced Cancer

France, United States, Spain, Australia, Italy, Switzerland, United Kingdom
University of Florence
Azienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaborators

Recruiting

RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment (RAISE)

Migraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura

Italy
Bill & Melinda Gates Medical Research Institute

Not yet recruiting

Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population

Healthy Volunteers

Kenya, Uganda
Bristol-Myers Squibb

Terminated

An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)

Advanced Cancer

United States, Spain, France, Austria, Italy, Australia, Canada, Switzerland
GlaxoSmithKline

Completed

Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral Feed Intolerance

Gastroparesis

Australia
EMD Serono
Merck KGaA, Darmstadt, Germany

Terminated

Atacicept in Multiple Sclerosis Extension Study, Phase II (ATAMS ext)

Relapsing Multiple Sclerosis

Sweden, United States, Czech Republic, Russian Federation, Spain, United Kingdom, Lithuania, Ukraine, Netherlands, Canada, Germany, France, Switzerland, Australia, Belgium, Lebanon, New Caledonia
Mayo Clinic
Pfizer

Not yet recruiting

Comparison of Rimegepant and Placebo for Pain in IBS

Irritable Bowel Syndrome

United States
Novartis

Completed

Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study

Hypertension

Slovakia, Italy, Netherlands, Argentina, Germany, Poland, Czech Republic, Iceland
Pfizer

Completed

Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)

Migraine

Japan
Hepion Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of Rencofilstat in Adult Subjects With NASH F3 (ALTITUDE)

NASH With Fibrosis

United States
EMD Serono

Completed

Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus (ADDRESS II)

Lupus Erythematosus, Systemic

Korea, Republic of, Philippines, Spain, United States, Czechia, Germany, United Kingdom, South Africa, Poland, Argentina, Italy, Chile, Bulgaria, Japan, Brazil, Mexico, Peru, Russian Federation
EMD Serono
Merck KGaA, Darmstadt, Germany

Completed

Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE) (APRIL-SLE)

Lupus Erythematosus, Systemic

United States, Croatia, Bulgaria, France, Korea, Republic of, Poland, Russian Federation, South Africa, Spain, United Kingdom, Germany, Malaysia, Latvia, Lithuania, Ukraine, Argentina, Israel, Netherlands, Greece, Taiwan, Philip... and more
PHARMENTERPRISES LLC

Not yet recruiting

Study to Evaluate the Efficacy and Safety of XC243 in Patients With Exacerbation of Chronic Cystitis

Cystitis

Russian Federation
NYU Langone Health

Active, not recruiting

Nivolumab Combined With BMS-986253 in HCC Patients

Hepatocellular Carcinoma

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment

Moderate Liver Impairment | Severe Liver Impairment

United States
Biohaven Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy (RESILIENT)

Neuromuscular Diseases | Spinal Muscular Atrophy | SMA

United States, Netherlands, United Kingdom, Spain, Czechia, Belgium, Germany, Italy, Poland
Bristol-Myers Squibb
Clovis Oncology, Inc.

Completed

A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer (FRACTION-GC)

Advanced Gastric Cancer

United States, Israel, Netherlands, Canada, Italy, Australia, Germany, Singapore, Switzerland
Imperial College Healthcare NHS Trust
Imperial College London; University of Oxford; Oxford University Hospitals NHS...

Withdrawn

SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations (SABRE)

Lymphoma | Leukemia | Immune Thrombocytopenia | SARS-CoV2 Infection | SARS-CoV-2 Acute Respiratory Disease | Myeloma | Thrombotic Thrombocytopenic Purpura (TTP)

United Kingdom
Sumitomo Pharma Co., Ltd.

Terminated

A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase

Schizophrenia

Japan, Taiwan, China, Philippines

Search clinical trials for: BMS-986004 75 mg IV

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations